Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 2 December 2025 - 6 December 2025

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly shares traded near $1,010 on December 6, 2025, with a market value just under $1 trillion after a brief pullback from record highs. The company cut list prices on Zepbound vials this week, pressuring margins and sending the stock lower. Zepbound and Mounjaro generated $10.1 billion in Q3 sales, making Lilly’s GLP-1 drugs the world’s top-selling franchise. Most analysts maintain Buy ratings, with 12-month targets around $1,060–$1,090.
6 December 2025
···
Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson shares closed at $201.90 on December 5, 2025, less than 3% below their 52-week high. The stock has climbed about 35% over the past year, fueled by earnings beats, acquisitions, and new clinical data. The company faces large talc litigation verdicts and plans to spin off its orthopaedics unit. Market capitalization stands near $485 billion.
6 December 2025
··
Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences shares closed at $121.22 on December 5, 2025, about 6% below their 52-week high. Third-quarter revenue rose 3% year-over-year to $7.8 billion, with HIV product sales up 4% to $5.3 billion. Veklury sales dropped as COVID cases fell. The company continues to invest in oncology and cell therapy despite near-term earnings pressure.
6 December 2025
···
Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly shares traded above $1,000 on December 5, 2025, after recently crossing a $1 trillion market cap, the first for a healthcare company. The stock is up over 30% year to date despite an 8% pullback in the past week. Lilly is cutting prices on its obesity drug Zepbound and preparing to seek accelerated approval for a new weight-loss pill. The company’s dividend yield remains around 0.6%.
5 December 2025
··
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK shares traded near multi-year highs on 4 December, closing at 1,826–1,837p in London and $48.57 in New York, up over 40% year-to-date. The company repurchased more than 11.5 million shares since late September as part of a £2 billion buyback. New executive share options were granted on 5 December. Market cap stands at about £73 billion in London and just under $100 billion in New York.
5 December 2025
··
Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen traded near $343 Thursday, close to record highs after a year of strong earnings and FDA approval for its lung-cancer drug Imdelltra. Shares are up about 34% year-to-date, outpacing the broader market. Trefis set a bullish $450 target, citing 12% revenue growth and $13 billion in free cash flow. EverSource Wealth Advisors cut its Amgen stake by nearly 28% in Q2.
4 December 2025
··
Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

BMO Capital raised its Regeneron price target to $850, citing Dupixent momentum and improved Eylea HD trends. Canaccord Genuity set a Street-high target of $1,057, expecting Dupixent growth to offset Eylea declines. Regeneron now holds a “Moderate Buy” consensus from 28 analysts, with an average target near $768. The stock has surged over 50% in six months amid active institutional trading.
4 December 2025
·
Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

Tonix Pharmaceuticals’ stock (NASDAQ: TNXP) closed near $19.98 on December 4, 2025, up roughly 10–12% for the day and about 10,515% over the past year. The surge follows FDA approval and U.S. launch of Tonmya, the first new fibromyalgia drug in over 15 years. Market cap stands near $190 million. Investors remain focused on whether Tonmya sales can offset heavy cash burn and potential dilution.
4 December 2025
··
Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

Bristol Myers Squibb shares rallied this week, trading near $50.55 after news on its Alzheimer’s drug Cobenfy, an AI drug discovery milestone, and a key lawsuit ruling. The company declared a $0.62 quarterly dividend, bringing the annual yield to about 4.9%. Market cap stands at $104 billion. Despite the rebound, BMY shares remain down roughly 15% for 2025.
4 December 2025
··
Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson traded near $206 on Wednesday, close to its 52-week high after a 40% rally this year. Guggenheim reiterated a Buy rating and $206 target, citing strong multiple myeloma trial results. Barclays raised its target to $197 but kept an Equal Weight rating. The company launched a vision-care campaign with Naomi Watts and received European approval for its autoimmune drug IMAAVY.
4 December 2025
··
Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Amgen shares closed at $345.42 on December 3, 2025, up 2% and setting a new 52-week high near $345.95. The stock has gained about 35% year-to-date and over 25% in the past year. Amgen beat Q3 earnings forecasts and raised full-year guidance, but analysts’ 12-month targets mostly remain below current prices. The consensus rating ranges from “Hold” to “Moderate Buy.”
3 December 2025
··
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer shares traded at $25.60 late December 3, 2025, near the midpoint of their 52-week range and well below 2021 highs. The stock yields about 6.5–7% and trades at 8–9x forward earnings after a $10 billion obesity-drug deal. Technical analysis points to support near $24.95 and resistance around $26.10. Market capitalization stands near $144 billion.
3 December 2025
···
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron shares traded near $725 midday December 3, down 2%, after Morgan Stanley downgraded the stock to Equal Weight with a $767 target, citing limited near-term upside. Eylea HD received U.S. approval for less frequent dosing in retinal vein occlusion. Market cap stands at about $77 billion, with a 0.5% dividend yield and trailing P/E of 17–18. Year-to-date total return is roughly 3%.
3 December 2025
··
Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

A U.S. judge on Dec. 1, 2025, revived a $6.7 billion lawsuit against Bristol-Myers Squibb over Celgene contingent value rights, sending BMY shares down 1.89% to $48.25. The stock marked its third straight loss, underperforming peers as legal risks weighed despite positive hematology data at ASH 2025. Market cap stood at about $98 billion. Trading volume was below average at 14.5 million shares.
3 December 2025
··
Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck shares traded near $101 on December 2, 2025, down about 1%, with a market cap above $250 billion after a 22% rally in November. The company raised its quarterly dividend to $0.85 per share, effective January 2026. Merck’s stock remains below its 52-week high of $105.84 and trades at a forward P/E of 11–11.5x, below sector averages.
2 December 2025
···
Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson closed at $206.92 on December 2, just below its record high of $207.56 from November 26. The company’s market cap stands near $500 billion after a 30% year-to-date stock surge, outpacing the S&P 500. Recent gains follow strong earnings, higher 2025 guidance, a new EU drug approval, and a $3.05 billion oncology acquisition.
2 December 2025
··
Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly shares traded near $1,060 midday December 2, just below record highs, after a year of sharp gains fueled by obesity and diabetes drugs. The company cut U.S. self-pay prices for Zepbound on December 1, following a federal deal to lower GLP-1 prices. Lilly’s market cap briefly topped $1 trillion in November, the first for a healthcare firm. WHO issued its first guideline recommending GLP-1 drugs for obesity on December 1.
2 December 2025
··
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK closed near 1,783p in London on 2 December 2025, just below its 52-week high, after strong Q2 and Q3 results lifted shares nearly 40% over 12 months. Q3 sales rose 8% at constant exchange to £8.5 billion, with oncology up 39% and core EPS up 14%. The ADR ended at $47.19 in New York. Analyst focus remains on the company’s growth pipeline and 2031 revenue targets.
2 December 2025
····
1 … 28 29 30 31 32 … 38

Stock Market Today

  • How Investors Can Buy SpaceX Stock Pre-IPO: 3 Key Options
    April 11, 2026, 5:11 AM EDT. SpaceX has confidentially filed for its IPO with the SEC, targeting a $1.75 trillion valuation and a potential $75 billion raise. Trading could start by July following a June roadshow. Investors unable to wait can gain exposure through three routes. The Ark Venture Fund offers 17% exposure but carries risks: a 2.9% expense ratio, limited quarterly liquidity, and heavy private company holdings. The Baron Partners Fund, with 33% SpaceX, boasts a 741% return over 10 years and allows more liquidity but focuses on fewer stocks. These funds provide pre-IPO opportunities but differ in risk and access. Retail investors eyeing SpaceX shares ahead of the blockbuster IPO should weigh fund structures, costs, and liquidity carefully.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 5:13 AM EDT How Investors Can Buy SpaceX Stock Pre-IPO: 3 Key Options April 11, 2026, 5:11 AM EDT. SpaceX has confidentially filed for its IPO with the SEC, targeting a $1.75 trillion valuation and a potential $75 billion raise. Trading could start by July following a June roadshow. Investors unable to wait can gain exposure through three routes. The Ark Venture Fund offers 17% exposure but carries risks: a 2.9% expense ratio, limited quarterly liquidity, and heavy private company holdings. The Baron Partners Fund, with 33% SpaceX,
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop